belzutifan + cabozantinib

Belzutifan + cabozantinib is an oral combination therapy of two small molecule drugs: **belzutifan**, a selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α), and **cabozantinib**, a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor (VEGFR), c-MET, AXL and multiple other receptor tyrosine kinases. This combination is designed to exert synergistic antitumor effects by simultaneously inhibiting hypoxia-driven signaling (via HIF-2α) and multiple pro-angiogenic and oncogenic kinetics (via MET, AXL, VEGFR, etc.). It is being investigated primarily for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC), and has shown promising response rates and disease control in phase 2 trials, both in treatment-naive and previously treated patients. The regimen is under clinical development, with support from Merck Sharp & Dohme and the National Cancer Institute[1][3][5][6][7].

Brand names

Cabometyx (cabozantinib)belzutifan + cabozantinib

Other names

belzutifan plus cabozantinibHIF-2α inhibitor and TKI combination